MONDAY, DECEMBER 11

7:00–8:30 AM
Session: Therapeutic Apheresis as an Immunomodulatory Tool Hematology Disease Topics & Pathways:
Presenter: Jeffrey L. Winters, M.D.
Bldg B, Lvl 5, Murphy BR 3-4 (Georgia World Congress Center)
Plasma Exchange for Thrombotic Microangiopathies Other Than Thrombotic Thrombocytopenic Purpura

8:15 AM
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Risk Factors and Response-Adapted Personalized Medicine
Presenter: James M. Foran, M.D.
Bldg B, Lvl 5, Murphy BR 1-2 (Georgia World Congress Center)
570 Molecular Epidemiology of Acute Myeloid Leukemia (AML): Novel Association of Clinical Epidemiologic Exposures with Unique Mutation Groups on Exome Sequencing of Leukemia DNA in the Mayo Clinic AML Epidemiology Cohort

10:45 AM
Session: 622. Lymphoma Biology—Non-Genetic Studies: Novel Mechanisms Implicated in Lymphoma Biology
Presenter: Tibor Bedekovics, Ph.D.
Bldg C, Lvl 1, C101 Aud (Georgia World Congress Center)
644 Catalytically Active UCH-L1 Is Required for MYC Driven B-Cell Lymphomagenesis

2:45–4:15 PM
Novel Therapeutics in Myeloma
Presenter: Shaji K. Kumar, M.D.
Bldg C, Lvl 1, Hall C2-C3 (Georgia World Congress Center)
Emerging Options in Multiple Myeloma: Targeted, Immune, and Epigenetic Therapies

3:45 PM
Session: 653. Myeloma: Therapy, excluding Transplantation I
Presenter: A. Keith Stewart, MBChB, MBA
Bldg C, Lvl 1, Hall C1 (Georgia World Congress Center)
743 Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial

4:45 PM
Session: 902. Health Services Research—Malignant Diseases: Race-Ethnic and Age-Related Disparities
Presenter: Sikander Ailawadhi
Bldg B, Lvl 2, B211-B212 (Georgia World Congress Center)
860 Factors Determining Utilization of Stem Cell Transplant (SCT) for Initial Therapy of Multiple Myeloma (MM) By Patient Race: Exploring Intra-Racial Healthcare Disparities

5:00 PM
Session: 642. CLL: Therapy, excluding Transplantation: New Agents, Infections, and PET/CT
Presenter: Tait D. Shanafelt, M.D.
Bldg B, Lvl 5, Murphy BR 3-4 (Georgia World Congress Center)
831 Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository
MONDAY, DECEMBER 11 CONTINUED

6:30 PM
Session: 904. Outcomes Research—Malignant Conditions: Survivorship and Quality of Life in Lymphoid Malignancies
Presenter: Priyanka Pophali, M.D.
Bldg B, Lvl 3, B312-B314 (Georgia World Congress Center)
914 The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival

7:30 PM
Session: 904. Outcomes Research—Malignant Conditions: Survivorship and Quality of Life in Lymphoid Malignancies
Presenter: Carrie A Thompson, M.D.
Bldg B, Lvl 3, B312-B314 (Georgia World Congress Center)
917 Changes in Quality of Life in Indolent Non-Hodgkin Lymphoma 3 Years after Diagnosis